Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Cipla Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (476)
Cancellation by sponsor (195)
Cancellation or suspension (77)
Prescription medicine registration (37)
Cancellation for failure to pay annual charge (17)
Australian Public Assessment Report (AusPAR) (4)
Prescription medicine decision summary (4)
Prescription medicine evaluation (1)

Date

2024 (73)
2023 (102)
2022 (74)
2021 (76)
2020 (120)
2019 (22)
2018 (69)
2017 (106)
2016 (31)
2015 (36)
2014 (21)
2013 (9)
2012 (5)
2011 (6)
2010 (20)
2009 (5)
2008 (3)
2007 (6)
2006 (7)
2005 (2)
2004 (2)
2003 (4)
2002 (3)
2001 (4)
2000 (1)
1999 (2)
1998 (1)
1996 (1)

Results for "[search-keyword]"

Search

Sponsor content

811 result(s) found, displaying 41 to 50

CIPLA TADALAFIL 20 tadalafil 20 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2024

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
CIPLA ENTECAVIR entecavir (as monohydrate) 1mg film coated tablets Cancelled under Section 30(1)(c) of the Act

28 June 2024

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
CIPLA ENTECAVIR entecavir (as monohydrate) 0.5 mg film coated tablets Cancelled under Section 30(1)(c) of the Act

28 June 2024

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
CIPLA PAIN RELIEF PARACETAMOL + CODEINE 10, paracetamol 500mg + codeine phosphate hemihydrate 10mg tablets blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2024

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
OMEGAPHARM IRINOTECAN irinotecan hydrochloride trihydrate 40 mg / 2 mL injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2024

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
OMEGAPHARM IRINOTECAN irinotecan hydrochloride trihydrate 100 mg / 5 mL injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2024

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
CIP APIXABAN apixaban 2.5 mg tablet blister pack (407826)

3 April 2024

ARTG

Australian Register of Therapeutic Goods (ARTG) information for CIP APIXABAN apixaban 2.5 mg tablet blister pack.
CIP APIXABAN apixaban 5 mg tablet blister pack (407827)

3 April 2024

ARTG

Australian Register of Therapeutic Goods (ARTG) information for CIP APIXABAN apixaban 5 mg tablet blister pack.
APIXABAN CIPLA apixaban 2.5 mg tablet blister pack (407820)

3 April 2024

ARTG

Australian Register of Therapeutic Goods (ARTG) information for APIXABAN CIPLA apixaban 2.5 mg tablet blister pack.
APIXABAN CIPLA apixaban 5 mg tablet blister pack (407825)

3 April 2024

ARTG

Australian Register of Therapeutic Goods (ARTG) information for APIXABAN CIPLA apixaban 5 mg tablet blister pack.

Pages

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Current page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.